

Datasheet



Mouse mAb to **CD44**
Clone **145-23**
Isotype **IgG1-κ**

Source

A BALB/c mouse was immunized with stimulated human leucocytes.
Fusion partner: SP2/0.

Specifications

145-23 reacts with CD44, a type 1 transmembrane glycoprotein providing cell-cell and cell-matrix adhesion while linked to the cytoskeleton. It is involved in haematopoiesis, lymphocyte homing and activation, and tumor metastasis. It binds to fibrin, hyaluronate and other matrix proteins. On tumors CD44H is highly expressed, suggesting an important role in progression for this isoform. CD44 also forms the protein backbone of the human erythrocyte Lutheran antigen system. The epitope of 145-23 is resistant to (chemo)trypsin digestion.




Figure 1: Human breast cancer stained with 145-23 (paraffin).

Species reactivity

Positive: human, mouse.

Applications

CD44 immunostaining is commonly used for the discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.

Flow cytometry	Frozen sections	Immunofluorescence	Paraffin sections	Western blot
+	+	+	Citrate	+

Format

Produced in tissue culture, contains no host Ig. Antibodies are affinity purified and presented in PBS with 0,02% sodium azide.
Stored at 4°C-8°C, shelf life is at least 24 months after purchase.

Dilution advice

- Flow cytometry (0,5-1,0 µg/million cells in 0,1 ml).
- Immunoblotting (1-2 µg/ml).
- Immunofluorescence (1-2 µg/ml).
- Immunohistology (formalin-fixed: 1-2 µg/ml for 30 min at RT: requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min, followed by cooling at RT for 20 minutes).

Positive control

HeLa cells, paracortex in tonsil or lymph node, human breast cancer.

Datasheet



References

- Leukocyte typing IV. White cell differentiation antigens. Proceedings of the 4th International Workshop and Conference, (Knapp, W et al., eds) Oxford University Press; (1989. p. 619-22).
- Nishina S. et al., *Graefes Archiv. Clin. Exp. Ophthalm.* **235**: 92-96 (1997).
- Horny H.P. et al. *Virchows Arch.* **429**: 91-94 (1996).